Alcohol craving medication
Pro Research Analysisby 
Searched over 200M research papers
Pharmacological Approaches to Reducing Alcohol Craving
Introduction to Alcohol Craving and Medication
Alcohol dependence is a significant public health issue, and craving is a critical factor that contributes to relapse. Various medications have been studied to reduce alcohol craving and support abstinence. This article synthesizes recent research on pharmacological treatments aimed at reducing alcohol craving in individuals with alcohol use disorder (AUD).
Naltrexone: Efficacy and Moderators
Naltrexone, an opioid antagonist, is one of the most studied medications for reducing alcohol craving. Research has shown that naltrexone can significantly reduce alcohol craving and consumption. For instance, a study demonstrated that naltrexone decreased both the desire to drink and the amount of alcohol consumed in alcohol-dependent subjects, potentially through its effects on the hypothalamo-pituitary-adrenocortical axis . Another study found that naltrexone reduced cravings and heavy drinking days, particularly in individuals with a high craving for alcohol and those with a sweet-liking phenotype . Additionally, extended-release naltrexone has been shown to reduce alcohol cravings and use behaviors during treatment and at follow-up .
Oxytocin and Naltrexone Combination
Combining oxytocin with naltrexone has shown promise in preliminary studies. The ON-ICE trial is investigating the combined effects of intranasal oxytocin and oral naltrexone on stress-induced and alcohol cue-induced craving. This combination aims to enhance the efficacy of naltrexone by leveraging oxytocin's beneficial effects on stress reactivity and alcohol craving .
Gabapentin: Reducing Consumption and Craving
Gabapentin, an anticonvulsant, has also been studied for its potential to reduce alcohol craving. A randomized, double-blind, placebo-controlled trial found that gabapentin significantly reduced the number of drinks per day, the percentage of heavy drinking days, and increased the percentage of days of abstinence compared to placebo . These findings suggest that gabapentin may be a valuable option for supporting abstinence in alcohol-dependent individuals.
Monoamine Stabilizers: OSU6162
The monoamine stabilizer OSU6162 has shown potential in reducing alcohol craving, particularly in individuals with high baseline impulsivity. A study found that OSU6162 significantly attenuated priming-induced craving and blunted the subjective liking of consumed alcohol, although it had no significant effect on cue-induced craving . These results indicate that OSU6162 may be beneficial for certain subgroups of alcohol-dependent individuals.
Acamprosate: Limited Efficacy in Craving Modulation
Acamprosate, another medication approved for treating AUD, has shown mixed results in reducing alcohol craving. A study evaluating the effects of acamprosate on pharmacologically induced craving found that it did not significantly influence craving levels induced by yohimbine or mCPP challenges . This suggests that while acamprosate may support abstinence, its efficacy in directly reducing craving may be limited.
Conclusion
Pharmacological treatments for alcohol craving have shown varying degrees of efficacy. Naltrexone remains a well-supported option, particularly when combined with oxytocin. Gabapentin and OSU6162 also show promise, especially for specific subgroups of patients. However, the effectiveness of acamprosate in reducing craving appears limited. Continued research is essential to optimize treatment strategies and improve outcomes for individuals with AUD.
Sources and full results
Most relevant research papers on this topic
Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial.
The sweet-liking phenotype and high craving for alcohol are associated with a strong response to naltrexone treatment in alcohol dependence.
Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.
Gabapentin effectively reduces alcohol consumption and cravings, potentially aiding patients in maintaining abstinence and supporting its potential use in alcohol withdrawal and dependence treatment.
The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: A human laboratory study.
OSU6162 shows potential in reducing priming-induced alcohol cravings in alcohol dependent individuals, but its effect on cue-induced cravings remains unclear.
DOI
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate
Yohimbine and mCPP challenges increase alcohol cravings in treatment-seeking alcoholics, but acamprosate does not affect these cravings at clinically used doses.
DOI